OXC4P1-105: A Phase I study of the safety, tolerability, and antitumor activity of escalating doses of combretastatin A4 phosphate given in combination with bevacizumab to subjects with advanced solid tumors

Trial Profile

OXC4P1-105: A Phase I study of the safety, tolerability, and antitumor activity of escalating doses of combretastatin A4 phosphate given in combination with bevacizumab to subjects with advanced solid tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2016

At a glance

  • Drugs Fosbretabulin (Primary) ; Bevacizumab
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Aug 2012 Actual end date changed from Jan 2007 to Sep 2007, as reported by ISRCTN: Current Controlled Trials.
    • 16 Aug 2012 New source identified and integrated (ISRCTN: Current Controlled Trials, 96787846).
    • 06 Jun 2012 Results have been published in Clinical Cancer Research according to a OXiGENE media release. Results were also summarised in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top